China Zenith Chemical Group Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de China Zenith Chemical Group.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Electric Utilities	10.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Why Investors Shouldn't Be Surprised By China Zenith Chemical Group Limited's (HKG:362) 27% Share Price Plunge

Dec 27

Is China Zenith Chemical Group (HKG:362) A Risky Investment?

Apr 28

Does Xinyang Maojian Group (HKG:362) Have A Healthy Balance Sheet?

May 23

How Many Xinyang Maojian Group Limited (HKG:362) Shares Have Insiders Sold, In The Last Year?

Mar 13

Xinyang Maojian Group (HKG:362) Has Debt But No Earnings; Should You Worry?

Feb 06

Xinyang Maojian Group's (HKG:362) Shareholders Are Down 87% On Their Shares

Dec 31

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como China Zenith Chemical Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:362 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	33	-515	-21	-13	N/A
9/30/2023	67	-331	-20	-12	N/A
6/30/2023	101	-147	-19	-11	N/A
3/31/2023	123	-45	N/A	N/A	N/A
12/31/2022	145	58	-41	2	N/A
9/30/2022	172	-97	-55	-12	N/A
6/30/2022	199	-251	-69	-26	N/A
12/31/2021	152	-312	N/A	N/A	N/A
9/30/2021	190	-335	N/A	N/A	N/A
6/30/2021	229	-359	-80	-61	N/A
3/31/2021	248	-416	-93	-74	N/A
12/31/2020	268	-381	N/A	N/A	N/A
9/30/2020	231	-368	N/A	N/A	N/A
6/30/2020	194	-355	-17	3	N/A
3/31/2020	236	-506	0	13	N/A
12/31/2019	278	-657	17	23	N/A
9/30/2019	300	-662	-44	-32	N/A
6/30/2019	323	-667	-104	-86	N/A
3/31/2019	359	-449	-76	-52	N/A
12/31/2018	396	-231	-48	-17	N/A
9/30/2018	382	-215	-34	-6	N/A
6/30/2018	368	-199	-20	5	N/A
12/31/2017	209	-125	-470	-426	N/A
9/30/2017	197	-124	N/A	-427	N/A
6/30/2017	186	-124	N/A	-429	N/A
12/31/2016	146	-409	N/A	-64	N/A
9/30/2016	107	-408	N/A	-6	N/A
6/30/2016	68	-407	N/A	52	N/A
3/31/2016	75	-325	N/A	39	N/A
12/31/2015	81	-229	N/A	25	N/A
9/30/2015	72	-239	N/A	20	N/A
6/30/2015	63	-249	N/A	14	N/A
3/31/2015	81	-387	N/A	22	N/A
12/31/2014	99	-525	N/A	30	N/A
9/30/2014	131	-542	N/A	-2	N/A
6/30/2014	163	-560	N/A	-34	N/A
3/31/2014	195	-418	N/A	-10	N/A
12/31/2013	227	-277	N/A	15	N/A
9/30/2013	262	-294	N/A	28	N/A
6/30/2013	297	-311	N/A	41	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 362 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 362 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 362 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 362 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 362 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 362 se prevé que sea elevada dentro de 3 años.

China Zenith Chemical Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

China Zenith Chemical Group Limited Provides Group Earnings Guidance for the Year Ended 30 June 2022

Xinyang Maojian Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 31 December 2021

Xinyang Maojian Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 31 December 2021

Recent updates

China Zenith Chemical Group Limited has completed a Follow-on Equity Offering in the amount of HKD 10.8 million.

China Zenith Chemical Group Limited has filed a Follow-on Equity Offering in the amount of HKD 10.8 million.

China Zenith Chemical Group Limited Announces That Ms. Chan Yuk Foebe Resigned as Executive Director and Chairman of the Board

China Zenith Chemical Group Limited Appoints Chin Chun Hin as an Executive Director

New major risk - Shareholder dilution

China Zenith Chemical Group Limited has completed a Follow-on Equity Offering in the amount of HKD 28 million.

China Zenith Chemical Group Limited to Report First Half, 2024 Results on Feb 15, 2024

Why Investors Shouldn't Be Surprised By China Zenith Chemical Group Limited's (HKG:362) 27% Share Price Plunge

China Zenith Chemical Group Limited, Annual General Meeting, Jan 18, 2024

Insider recently sold HK$354k worth of stock

New major risk - Market cap size

Less than half of directors are independent

China Zenith Chemical Group Limited to Report Fiscal Year 2023 Results on Nov 01, 2023

Full year 2023 earnings released: HK$0.46 loss per share (vs HK$9.81 loss in FY 2022)

New minor risk - Financial data availability

China Zenith Chemical Group Limited to Report Fiscal Year 2023 Results on Sep 28, 2023

Less than half of directors are independent

New minor risk - Financial data availability

China Zenith Chemical Group Limited Announces Board Changes

Insider recently bought HK$67k worth of stock

New minor risk - Share price stability

China Zenith Chemical Group Limited announced that it has received HKD 28.6 million in funding

First half 2023 earnings released: EPS: HK$1.88 (vs HK$0.074 in 1H 2022)

Insider recently bought HK$5.4m worth of stock

China Zenith Chemical Group Limited to Report Q2, 2023 Results on Feb 28, 2023

Less than half of directors are independent

China Zenith Chemical Group Limited, Annual General Meeting, Dec 07, 2022

Full year 2022 earnings released: HK$0.49 loss per share (vs HK$0.31 loss in FY 2021)

China Zenith Chemical Group Limited to Report Fiscal Year 2022 Results on Sep 29, 2022

China Zenith Chemical Group Limited Provides Group Earnings Guidance for the Year Ended 30 June 2022

Insider recently bought HK$307k worth of stock

China Zenith Chemical Group Limited announced that it expects to receive HKD 35.4 million in funding

China Zenith Chemical Group Limited announced that it expects to receive HKD 35.4 million in funding

Insider recently bought HK$2.8m worth of stock

Less than half of directors are independent

Executive Vice Chairman recently bought HK$156k worth of stock

China Zenith Chemical Group Limited Appoints Mr. Liu Yang Yang as Non-Executive Director, with Effect from May 26, 2022

China Zenith Chemical Group Limited announced a financing transaction

Is China Zenith Chemical Group (HKG:362) A Risky Investment?

Insider recently sold HK$2.0m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Xinyang Maojian Group Limited to Report Q2, 2022 Results on Feb 21, 2022

Xinyang Maojian Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 31 December 2021

Insider recently bought HK$25m worth of stock

Xinyang Maojian Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 31 December 2021

Less than half of directors are independent

Shie Thomas cancelled the acquisition of 28.28% stake in Xinyang Maojian Group Limited (SEHK:362) from Chan Yuen Tung.

Less than half of directors are independent

Does Xinyang Maojian Group (HKG:362) Have A Healthy Balance Sheet?

Executive Director has left the company

How Many Xinyang Maojian Group Limited (HKG:362) Shares Have Insiders Sold, In The Last Year?

New 90-day low: HK$0.29

New 90-day high: HK$0.41

First half 2021 earnings released: HK$0.054 loss per share (vs HK$0.035 loss in 1H 2020)

Xinyang Maojian Group (HKG:362) Has Debt But No Earnings; Should You Worry?

Xinyang Maojian Group Limited (SEHK:362) entered into an agreement to acquire Beijing Yaolai Longwei Wine Co., Ltd. from Yuan Lin, Chen Jing and Jiang Qiaowei for HKD 80 million.

Xinyang Maojian Group Limited to Report First Half, 2021 Results on Feb 05, 2021

New 90-day low: HK$0.32

New 90-day low: HK$0.34

Xinyang Maojian Group's (HKG:362) Shareholders Are Down 87% On Their Shares

Xinyang Maojian Group Limited, Annual General Meeting, Dec 09, 2020

Independent Non-Executive Director recently sold HK$742k worth of stock

Xinyang Maojian Group Limited announced that it expects to receive HKD 100 million in funding

Insider recently bought HK$12m worth of stock

Full year earnings released - HK$0.22 loss per share

Xinyang Maojian Group Limited to Report Fiscal Year 2020 Results on Sep 30, 2020

Xinyang Maojian Group Limited announced that it expects to receive funding from Huashang Financial Group Co. Limited

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento